Table 2.
Compliance with anamorelin administration and reasons for discontinuation
| N = 229 | ||
|---|---|---|
| Anamorelin administration duration | Median (Range) | 62 (1–629) days |
| Duration category | < 11 weeks/ ≥ 12 weeks | 135 (59%)/94 (41%) |
| Reasons for discontinuation and median duration | Disease progression | 63 cases, 27 (3–77) days |
| Patient request | 12 cases, 36 (1–70) days | |
| Nausea | 5 cases, 5 (4–22) days | |
| Hyperglycemia | 3 cases, 20 (3–76) days | |
| Abdominal distension | 3 cases, 11 (6–79) days | |
| Fatigue | 1 case, 50 days | |
| Increased salivation | 1 case, 38 days | |
| Cholangitis | 1 case, 17 days | |
| Decreased appetite | 1 case, 1 day | |
| Conversion surgery | 2 cases, 35 (14–42) days | |
| Unknown | 43 cases, 41 (2–79) days |